Skip to main content
Caplight Logo









Optieum Biotechnologies

Optieum Biotechnologies

Private
JapanHealthcare & Life Scienceshttps://optieumbio.com/

Last Round

Grant

Mar 18, 2025

Total Funding Raised

$11.09M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Optieum Biotechnologies is a biotechnology company that develops antibody-based therapies intended to treat cancer and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

CAR-T cell therapycell therapysolid tumor therapyCAR discovery platformplatform biotechimmunotherapyglioblastoma therapyscFv optimizationantibody-based therapydrug discoveryCAR-NK cell therapyautoimmune disease therapypreclinical biotechCDMO partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Optieum Biotechnologies Comparables

Compare Optieum Biotechnologies with similar companies based on industry and business-model similarity.

Optieum Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Noile-Immune Biotech
84%
Autolus
70%
ProMab Biotechnologies
65%

Optieum Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 18, 2025
Series AJan 14, 2025
GrantJan 27, 2022
SeedSep 30, 2021

Key People

Founding team and executive leadership

Shun Nishioka

Chief Executive Officer

Executive Team

Mikio C.

CFO

Executive Team

Optieum Biotechnologies Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 214% MoM, from 402 to 1.3K.

  • Jul 17, 2026

    Grew 21% QoQ, from 14 to 17 employees.

Optieum Biotechnologies Filings

Explore SEC and related filing metadata, where available.

Optieum Biotechnologies filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Optieum Biotechnologies's valuation, stock price, and market status.

Is Optieum Biotechnologies a public or private company?

Optieum Biotechnologies is a private company.

What is the current stock price of Optieum Biotechnologies?

Optieum Biotechnologies is a private company with no public stock price. No recent secondary market data is available.

How much is Optieum Biotechnologies worth (valuation)?

Valuation information for Optieum Biotechnologies is not publicly available.

Can I buy Optieum Biotechnologies stock?

Optieum Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Optieum Biotechnologies's last funding round?

Optieum Biotechnologies's most recent funding round was Grant on March 18, 2025.

Who are the main investors in Optieum Biotechnologies?

Key investors in Optieum Biotechnologies include Saisei Ventures, ANRI株式会社.

Will Optieum Biotechnologies IPO soon?

No public IPO plans have been announced for Optieum Biotechnologies.

How can I track Optieum Biotechnologies secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Optieum Biotechnologies's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersJapan
Employee Range15
Year Founded2020
Last FundingMar 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?